Uniphar PLC
LSE:UPR
Intrinsic Value
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. [ Read More ]
The intrinsic value of one UPR stock under the Base Case scenario is 487.78 GBX. Compared to the current market price of 218 GBX, Uniphar PLC is Undervalued by 55%.
Valuation Backtest
Uniphar PLC
Run backtest to discover the historical profit from buying and selling UPR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Uniphar PLC
Current Assets | 507.9m |
Cash & Short-Term Investments | 85.7m |
Receivables | 237.6m |
Other Current Assets | 184.7m |
Non-Current Assets | 781.6m |
Long-Term Investments | 25k |
PP&E | 206.7m |
Intangibles | 561.7m |
Other Non-Current Assets | 13.3m |
Current Liabilities | 574m |
Accounts Payable | 490.3m |
Other Current Liabilities | 83.7m |
Non-Current Liabilities | 382.8m |
Long-Term Debt | 348.7m |
Other Non-Current Liabilities | 34.1m |
Earnings Waterfall
Uniphar PLC
Revenue
|
2.6B
EUR
|
Cost of Revenue
|
-2.2B
EUR
|
Gross Profit
|
390m
EUR
|
Operating Expenses
|
-312.6m
EUR
|
Operating Income
|
77.4m
EUR
|
Other Expenses
|
-32.5m
EUR
|
Net Income
|
44.8m
EUR
|
Free Cash Flow Analysis
Uniphar PLC
UPR Profitability Score
Profitability Due Diligence
Uniphar PLC's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Uniphar PLC's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
UPR Solvency Score
Solvency Due Diligence
Uniphar PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Uniphar PLC's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
UPR Price Targets Summary
Uniphar PLC
According to Wall Street analysts, the average 1-year price target for UPR is 404.67 GBX with a low forecast of 336.38 GBX and a high forecast of 481.19 GBX.
Shareholder Return
UPR Price
Uniphar PLC
Average Annual Return | 41.97% |
Standard Deviation of Annual Returns | 68.12% |
Max Drawdown | -59% |
Market Capitalization | 696.2m EUR |
Shares Outstanding | 273 020 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Uniphar Plc engages in the provision of pre-wholesale and wholesale pharmaceutical distribution. The company is headquartered in Dublin, Dublin and currently employs 2,920 full-time employees. The company went IPO on 2019-07-17. The firm is a diversified healthcare services company. The company serves multinational pharmaceutical and medical technology manufacturers across three divisions: Commercial & Clinical, Product Access and Supply Chain & Retail. Through commercial & clinical division, the Company provides sales, marketing and distribution solutions to multinational pharmaceutical and medical device manufacturers on an outsourced basis. Product Access division offers two service offerings: On Demand Access and Exclusive Access. On Demand Access is a pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists. Exclusive Access is a manufacturer led solution for controlling the release of specialty medicines for specifically approved patient populations. Supply Chain & Retail provides both pre-wholesale distribution and wholesale distribution of pharmaceutical, healthcare and animal health products.
Contact
IPO
Employees
Officers
The intrinsic value of one UPR stock under the Base Case scenario is 487.78 GBX.
Compared to the current market price of 218 GBX, Uniphar PLC is Undervalued by 55%.